CXCL10 and cancer: Furthermore, Mitsugu and his colleagues found that mouse DC1s displayed phenotypic characteristics consistent with mature dendritic cells and secreted elevated amounts of IL-12 and CXCL10, thereby indicating the pivotal involvement of CXCL10 in both the immunogenic and therapeutic efficacy of dendritic cell-based cancer immunotherapy strategies [18].